QHSLab, Inc.

QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. In the first nine months of this year, QHSLab conducted over 30,000 digital medicine assessments through healthcare providers, encompassing mental health evaluations, allergy and asthma assessments, psychological screenings, chronic pain monitoring, and more.

As the allergy crisis continues to rise, more than sixty million Americans suffer from an allergic disease. Approximately 47% of American adults have some form of hypertension, and less than half of those individuals have their blood pressure under control. We know that stress levels among members of modern American society are higher than ever.

The challenges primary care physicians face extend beyond just the shortage. These healthcare professionals shoulder an average of $200,000 in medical school debt and are often overwhelmed by patient demand, leading to physician burnout. In these trying times, they need practical tools and support to continue delivering quality patient care while maintaining their practices with a growing revenue source.

While many are skeptical about the future of AI, it's undeniable that it's revolutionizing the healthcare industry. Forbes Tech Council recently published "10 Ways AI Is Advancing Healthcare." Based on this article, QHSLab is a "perfect 10" for improving clinical outcomes and increasing practice revenue for healthcare providers.

Healthcare providers are acutely aware of the impact of physical and mental health conditions on patients. While the connection between allergies and depression may seem unexpected, recent research underscores the importance of understanding this relationship. Moreover, we recognize that comprehensive screenings, such as those provided by QHSLab, are essential in assessing allergy baseline and mental health conditions like depression using tools such as the PHQ-GAD16 and Q-Scale.

In today's fast-paced world, mental health has emerged as a critical concern, with conditions like depression and anxiety negatively impacting multiples of millions of Americans. Surprisingly, many struggling with mental illness do not seek the help they need, often avoiding routine annual wellness visits (AWV) altogether. However, research shows that integrating regular depression and anxiety screenings into check-ups can be a game-changer in identifying and addressing these issues. Your patient's mental health is as vital as measuring blood pressure, body weight, and temperature, and assessing mental well-being has become increasingly crucial for maintaining overall health.

As the back-to-school season approaches, excitement and anticipation sweep over children, college students - and their parents alike. However, this transitional period can also trigger significant anxiety for many individuals. Here's how QHSLab's cutting-edge mental health assessments and interventions, including the PHQ9-GAD7 and the Q-Scale, are helping physicians address and manage these concerns.